Generic Name and Formulations:
Azilsartan medoxomil, chlorthalidone; 40/12.5mg, 40/25mg; tabs.
Arbor Pharmaceuticals, LLC
Indications for EDARBYCLOR:
Hypertension in patients not adequately controlled with monotherapy. As initial therapy in patients likely to need multiple drugs to achieve blood pressure goals.
≥18yrs: initially 40/12.5mg once daily; may increase to 40/25mg after 2–4 weeks as needed. Max: 40/25mg. Patients titrated to the individual components: may give corresponding dose of Edarbyclor. See full labeling.
<18yrs: not established.
Anuria. Concomitant aliskiren-containing products in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before starting therapy; monitor for hypotension. Renal impairment: monitor; consider discontinuing if impairment progresses. Severe CHF. Renal artery stenosis. Severe hepatic impairment. Monitor serum electrolytes periodically. Gout. Neonates. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; avoid or monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors; monitor renal function esp. in elderly and/or volume-depleted. May potentiate lithium; monitor. Concomitant digitalis may exacerbate hypokalemia.
Angiotensin II receptor blocker (ARB) + thiazide-like diuretic.
Dizziness, fatigue, hypotension, elevated serum creatinine; hypokalemia, hyponatremia, hyperuricemia.
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D